TL;DR
This study reveals that ANGPTL3, a protein known for its role in lipid metabolism, also directly drives the progression of atherosclerosis by activating M1 macrophages within plaques. This dual action suggests ANGPTL3 is a promising therapeutic target for both lowering blood lipids and reducing inflammation in atherosclerotic disease.
What Problem Does This Paper Address?
Atherosclerosis, a leading cause of cardiovascular disease, is driven by a complex interplay of lipid dysregulation and chronic inflammation. While lipid-lowering therapies like statins and PCSK9 inhibitors are effective, they don't fully prevent cardiovascular events, suggesting that inflammation also plays a critical role. Similarly, anti-inflammatory drugs, while reducing cardiovascular events, don't impact lipid levels. This highlights a critical need for therapeutic strategies that can simultaneously address both dyslipidemia and inflammation. Angiopoietin-like protein 3 (ANGPTL3) has emerged as a novel target for lipid-lowering due to its inhibition of lipoprotein lipase. However, its potential role in the inflammatory component of atherosclerosis remained unclear. This paper investigates whether ANGPTL3, beyond its lipid-lowering effects, directly influences macrophage behavior within atherosclerotic plaques, contributing to disease progression.
Methods
The researchers employed a multi-pronged approach:
- In vivo studies: They used mouse models of atherosclerosis (Ldlr-/- on a high-fat diet and ApoE-/- on a chow diet) and manipulated ANGPTL3 levels. This involved using adeno-associated virus (AAV) vectors to overexpress ANGPTL3 in the liver. They also created ANGPTL3 knockout (DKO) mice to study the effects of ANGPTL3 deficiency. Atherosclerotic plaque size, macrophage infiltration (using CD68 staining), and smooth muscle cell content (using α-SMA staining) were quantified. To track ANGPTL3's location, they used AAV vectors expressing FLAG-tagged ANGPTL3 and then immunostained for the FLAG tag in plaque tissue.
- In vitro studies: Human THP-1 cells, a monocytic cell line, were used to investigate ANGPTL3's direct effects on macrophage function. They examined ANGPTL3's interaction with integrin αvβ3 on macrophages and its impact on inflammatory pathways.
- Molecular analyses:
- Phospho-proteomics and proteomics: These techniques were used to identify proteins and their phosphorylation states that were altered by ANGPTL3 treatment in THP-1 cells, providing insights into signaling pathways.
- Western blotting and qPCR: Used to confirm protein and mRNA expression levels of key molecules like ANGPTL3, TLR4, and phosphorylated Akt.
- ELISA: Employed to measure circulating ANGPTL3 levels, cholesterol, triglycerides, and lipoprotein lipase (LPL) activity.
- Flow cytometry (FACS): Used to quantify the expression of integrin αvβ3 on THP-1 cells.
- Migration assays: Assessed the migratory capacity of THP-1 cells in response to ANGPTL3.
- NF-κB activity assays: Measured the activation of the NF-κB pathway, a key inflammatory signaling cascade.
- Human plaque analysis: ANGPTL3 presence was confirmed in human atherosclerotic plaque samples using immunostaining.
Datasets
Not discussed in the paper.
Key Insights and Ideas
- ANGPTL3's dual role: The study strongly suggests ANGPTL3 is not just a lipid regulator but also a direct driver of atherosclerotic plaque inflammation. This is a significant expansion of its known function.
- Plaque homing mechanism: ANGPTL3 appears to actively "home" to atherosclerotic plaques, likely through binding to integrin αvβ3 on macrophages. This provides a mechanism for its localized inflammatory effects.
- M1 macrophage polarization: ANGPTL3 directly promotes the activation and polarization of macrophages towards the pro-inflammatory M1 phenotype. This is a critical step in the development and progression of atherosclerosis.
- TLR4 and NF-κB activation: The study identifies Toll-like receptor 4 (TLR4) and the NF-κB pathway as key mediators of ANGPTL3's inflammatory effects on macrophages. ANGPTL3 enhances TLR4 expression, making macrophages more responsive to inflammatory stimuli like LPS.
- Akt phosphorylation as a key step: The study highlights the role of Akt phosphorylation in mediating ANGPTL3's effects on TLR4 expression, suggesting a specific signaling cascade involved.
- Therapeutic implications: Targeting ANGPTL3 could offer a "one-two punch" approach, simultaneously lowering blood lipids and dampening the inflammatory response within atherosclerotic plaques.
Key Results
- In vivo: Hepatic overexpression of ANGPTL3 significantly increased atherosclerotic plaque size and CD68+ macrophage infiltration in mouse models. Conversely, ANGPTL3 deficiency (DKO mice) attenuated plaque progression, reduced cholesterol and triglyceride levels, and lowered eotaxin levels. FLAG-tagged ANGPTL3 was detected within atherosclerotic plaques, confirming its homing.
- In vitro: ANGPTL3 FBN domain treatment of THP-1 cells led to increased production of pro-inflammatory cytokines (IL-1β, TNF-α, MIP-α), promoted M1 macrophage polarization (indicated by increased iNOS and decreased arginase 1 expression), and enhanced TLR4 expression.
- Signaling pathways: ANGPTL3 treatment induced Akt phosphorylation, which was crucial for increased TLR4 expression. This effect was dependent on integrin β3. ANGPTL3 also significantly amplified NF-κB activation in response to LPS.
- Human relevance: ANGPTL3 was detected in human atherosclerotic plaques, supporting its role in human disease.
Limitations and Future Work
The authors acknowledge several limitations:
- Phospho-proteomics validation: While a large number of phosphorylation sites were identified, validating each one with specific antibodies was not feasible.
- TLR4 transcription mechanism: The study showed that inhibiting Akt phosphorylation reduced TLR4 protein but not mRNA levels, indicating that the transcriptional regulation of TLR4 by ANGPTL3 remains unclear.
- Contribution of lipid reduction: It's difficult to completely disentangle the effects of ANGPTL3 on plaque size from its lipid-lowering effects in the DKO mice.
- Integrin β3 editing efficiency: In the integrin β3 deficient THP-1 cells, the editing efficiency was not complete, leading to mixed clones. This made it challenging to definitively confirm the role of integrin β3 in ANGPTL3's effects.
Future work could focus on:
- Elucidating the precise transcriptional mechanisms by which ANGPTL3 regulates TLR4.
- Developing stable cell lines with complete deletion of the RGD sequence in integrin β3 to further dissect its role.
- Investigating the specific role of eotaxin in ANGPTL3-mediated atherosclerosis.
- Exploring the therapeutic potential of ANGPTL3 inhibition using mAbs or small interfering RNA in more detail.
Summary updated